The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Severing ties with Canada, becoming a non-resident, tax obligations, and tax on Canadian-source income Benefits, credits and taxes for newcomers to Canada (immigrants and returning residents) Tax ...

There are two main types of lung cancer, called non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Each is treated differently with chemotherapy. Non-Small Cell Lung Cancer ...

Cancer treatment has seen significant advancements in recent years with the introduction of innovative therapies. AstraZeneca’s Imfinzi (durvalumab) has emerged as a key contributor in this evolution.

Top-line results from the AEGEAN trial of AZ's PD-L1 inhibitor Imfinzi (durvalumab) plus chemotherapy given pre-surgery for resectable NSCLC tumours have revealed a significant improvement in the ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80 to 85% of all cases of lung cancer. There are different stages of NSCLC, ranging from 0 to 4; ...

I expect AstraZeneca's revenue to continue to grow in the coming years, driven mainly by rising demand for Ultomiris, Strensiq, Farxiga, Imfinzi, Lokelma, Breztri, and regulatory approvals of its ...

Why is human resources so important for small businesses? Smaller businesses rely on close-knit teams to get the job done, so it’s vital to manage your human resources correctly. Understanding the ...

Both Tagrisso and Imfinzi have been recommended by England ... surgical resection in adults with stage 1B to 3A non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor ...

Tagrisso has been recommended as an adjuvant therapy following complete surgical resection in adults with stage 1B to 3A non-small cell lung cancer (NSCLC ... Meanwhile, Imfinzi has been ...